Hemolytic-uremic syndrome diagnostic study of choice: Difference between revisions
No edit summary |
No edit summary |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{HUS}} | {{HUS}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{S.G.}} | ||
== Overview == | == Overview == | ||
There is no single diagnostic study of choice for the diagnosis of HUS. | There is no single diagnostic study of choice for the diagnosis of HUS. | ||
| Line 7: | Line 7: | ||
== Diagnostic Study of Choice == | == Diagnostic Study of Choice == | ||
There is no single diagnostic study of choice for the diagnosis of HUS, but HUS can be diagnosed based on | There is no single diagnostic study of choice for the diagnosis of [[Hemolytic-uremic syndrome|hemolytic uremic syndrome]] ([[Hemolytic-uremic syndrome|HUS]]), but [[HUS]] can be [[Diagnose|diagnosed]] based on clinical presentation along with lab findings of [[microangiopathic hemolytic anemia]] with low [[Hemoglobin|hemoglobin (Hb)]], low [[haptoglobin]], high [[reticulocyte count]] and negative [[coombs test]], [[thrombocytopenia]] with [[Platelet|platelets]] less than 60,000 along with [[abnormal]] [[renal function]] as indicated with high [[blood urea nitrogen]] [[Blood urea nitrogen|(BUN)]] and [[creatinine]] and [[electrolyte abnormalities]]. A diagnosis of atypical hemolytic uremic syndrome requires testing for antibodies to complement factors H and I or testing for mutations in complement proteins or receptors.<ref name="pmid29327071">{{cite journal| author=Wong EKS, Kavanagh D| title=Diseases of complement dysregulation-an overview. | journal=Semin Immunopathol | year= 2018 | volume= 40 | issue= 1 | pages= 49-64 | pmid=29327071 | doi=10.1007/s00281-017-0663-8 | pmc=5794843 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29327071 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 14:30, 21 December 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome diagnostic study of choice |
|
Hemolytic-uremic syndrome diagnostic study of choice in the news |
|
Blogs on Hemolytic-uremic syndrome diagnostic study of choice |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There is no single diagnostic study of choice for the diagnosis of HUS.
Diagnostic Study of Choice
There is no single diagnostic study of choice for the diagnosis of hemolytic uremic syndrome (HUS), but HUS can be diagnosed based on clinical presentation along with lab findings of microangiopathic hemolytic anemia with low hemoglobin (Hb), low haptoglobin, high reticulocyte count and negative coombs test, thrombocytopenia with platelets less than 60,000 along with abnormal renal function as indicated with high blood urea nitrogen (BUN) and creatinine and electrolyte abnormalities. A diagnosis of atypical hemolytic uremic syndrome requires testing for antibodies to complement factors H and I or testing for mutations in complement proteins or receptors.[1]
References
- ↑ Wong EKS, Kavanagh D (2018). "Diseases of complement dysregulation-an overview". Semin Immunopathol. 40 (1): 49–64. doi:10.1007/s00281-017-0663-8. PMC 5794843. PMID 29327071.